Originally Posted by
MAC
By negativity I’m referring to your previous posts over the last six months in regard to risk, or perhaps I'm perceiving negativity in lieu of rather extreme conservatism.
Five years from the recent first commercialisation announcement takes us to HY18, though the PEB goal may well be achieved ahead of that as the $20.5M capital boost does have a purpose.
I think you may in this instance garner greater respect if you made that disclosure Paper Tiger, but I respect that you may genuinely hold a valuation based on the extents of each conservative assumption. Low, perhaps very safe, but not necessarily representative, I just prefer more balanced assessments so there are margins on both sides.
I would agree though that the range of possible valuation scenarios is large, as it is for all ventures at this stage. I’ve a scenario range based on US cxbladder sales only of FY14 $1.45 through $2.30, though the more I study the company and the market, and share information, the more I settle toward the higher end of that spectrum.
Hope your gecko's find a new home.